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Abstract
Cells require distinct adhesion complexes to form contacts with their neighbors or the extracellular matrix, and vinculin links
these complexes to the actin cytoskeleton. Metavinculin, an isoform of vinculin that harbors a unique 68-residue insert in its
tail domain, has distinct actin bundling and oligomerization properties and plays essential roles in muscle development and
homeostasis. Moreover, patients with sporadic or familial mutations in the metavinculin-specific insert invariably develop
fatal cardiomyopathies. Here we report the high resolution crystal structure of the metavinculin tail domain, as well as the
crystal structures of full-length human native metavinculin (1,134 residues) and of the full-length cardiomyopathy-
associated DLeu954 metavinculin deletion mutant. These structures reveal that an a-helix (H19) and extended coil of the
metavinculin insert replace a-helix H1 and its preceding extended coil found in the N-terminal region of the vinculin tail
domain to form a new five-helix bundle tail domain. Further, biochemical analyses demonstrate that this helix replacement
directs the distinct actin bundling and oligomerization properties of metavinculin. Finally, the cardiomyopathy associated
DLeu954 and Arg975Trp metavinculin mutants reside on the replaced extended coil and the H19 a-helix, respectively. Thus,
a helix replacement mechanism directs metavinculin’s unique functions.
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Introduction
The morphology and functions of specialized cells within tissues
such as muscle requires unique organization of the actin
cytoskeleton, but how this is controlled is poorly understood. At
one level this relies on proper links of the actin network to
cadherin receptor-mediated cell-cell adherens junctions, to
integrin receptor-directed focal adhesions, and to intercalated
discs that are required for muscle cell function and that orchestrate
coordinated movement. These links are provided in part by
vinculin, a highly conserved and structurally dynamic protein that
stabilizes adhesions complexes [1] and which binds to actin
through the agency of its five-helix bundle tail (Vt) domain [2].
Accordingly, in the mouse vinculin loss leads to defects in adhesion
complexes that compromise embryonic cardiac development [3]
and vinculin
+/2 mice develop dilated cardiomyopathy [4].
All muscle cell types selectively express an alternatively spliced
isoform of vinculin, coined metavinculin, which harbors a 68-
residue insert positioned between a-helices H1 and H2 of the Vt
domain. Metavinculin levels are tightly controlled by signals
regulating muscle function, where for example changes in
mechanical load induce marked increases in levels of metavinculin
protein [4,5]. Importantly, metavinculin functions are also
essential for maintaining the architecture of muscle actin-
membrane attachment sites, as dilated cardiomyopathy (DCM)
in man is associated with reductions in metavinculin levels [6].
Furthermore, recurrent familial and sporadic mutations in residues
in the insert of metavinculin, like mutations in actin, are associated
with severe idiopathic DCM [6,7,8]. Three such mutations in
metavinculin have been described (Ala934Val, DLeu954, and
Arg975Trp) and they differ in their severity of disease and effects
on actin bundling. Specifically, the most severe mutant Arg975Trp
is associated with both dilated (DCM) and hypertrophic (HCM)
cardiomyopathies in man where it disrupts the organization of
intercalated discs, results in a pI drop of about 1.4 pH units for
residues 966–983, augments cross-linking of actin filaments [8],
and may compromise the interactions of metavinculin with its
partners, including vinculin [9]. By contrast, the DLeu954 and
Ala934Val mutations are specifically associated with DCM and
have more modest effects on the cross-linking of actin filaments,
especially the Ala934Val mutation [7].
The functions of vinculin as a regulator of adhesion signaling
and cell migration are well established [1,10,11], yet the specific
functions that metavinculin plays in muscle cells remain obscure.
Metavinculin is always co-expressed with vinculin in muscle but,
unlike vinculin, it cannot homodimerize and rather forms
heterodimers with vinculin, an interaction thought important for
metavinculin functions [5]. Furthermore, metavinculin has been
suggested to differ in the intramolecular interactions of its head
and tail domains that clamp vinculin in its inactive, closed
conformation [7], and it displays reduced binding to the acidic
phospholipid PIP2, which promotes oligomerization of activated
vinculin [5]. Importantly, although its insert does not bind to actin
[5], metavinculin differs markedly from vinculin in its control of
the actin network, where the metavinculin tail (MVt) domain (a
surrogate for activated metavinculin) induces a fine meshwork of
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bundles [12]. Finally, MVt displays higher affinity for the hnRNP
protein raver1 that co-localizes with metavinculin and vinculin at
intercalated discs in cardiomyocytes [5,13,14], and which appears
to deliver its mRNA cargo to nascent adhesion complexes via its
interactions with activated vinculin [15,16].
Vinculin is comprised of five helical bundle domains, four of
which (Vh1, Vh2, Vh3, and Vt2) reside in the globular head (VH)
of the molecule [17]. These are connected to Vt by a flexible
proline-rich hinge domain that allows vinculin to spring open
when the intramolecular contacts between its head and tail
domains are severed by the binding of activators such as talin
[18,19,20,21]. By contrast, the structures of inactive and activated
metavinculin are unknown.
Here, we present the first crystal structures of the human
metavinculin tail domain and of full-length (124 kDa) metavincu-
lin. These structures reveal that metavinculin harbors a unique a-
helix (H19) and a distinct preceding extended coil in its tail domain
that replace the H1 a-helix and its preceding extended coil found
in vinculin, which create a new five-helix bundle. Further, this
helix replacement controls metavinculin’s unique oligomerization
and actin bundling functions. Finally, the crystal structure and
analyses of metavinculin HCM and/or DCM mutants reveal that
the unique architecture of metavinculin is affected by these fatal,
recurrent mutations. Thus, a helix replacement mechanism
mediates metavinculin functions.
Results
The crystal structures of metavinculin reveal a helix
replacement mechanism
To define the molecular underpinnings of metavinculin’s
unique functions we solved the crystal structures of full-length
human metavinculin (124 kDa) and its tail domain to 3.4 A ˚ and
2.2 A ˚ resolution, respectively (Figure 1; Tables 1 and 2). The
structure of the globular head (VH) domain (residues 1–843) of
metavinculin is nearly identical to that of vinculin [17] with a root
mean square deviation (r.m.s.d.) of 1.57 A ˚ for 575 Ca atoms when
compared with that of vinculin.
The 68-residue insert in metavinculin lies between a-helices H1
and H2 of Vt, between residues 915 and 916. It has been assumed
that this domain would protrude from the 915–916 residue link,
leaving the five-helix bundle of Vt unchanged. Surprisingly, our
crystal structures show that this is not the case. Rather, an a-helix
of the metavinculin insert (coined H19) and its amino-terminal
extended coil replace the H1 a-helix and its amino-terminal
extended coil that are present in Vt, which are no longer part of
the MVt domain but are rather disordered in the metavinculin
structure (Figure 1; Supplementary Figures S1, S2, S3). Indeed,
the H19 for H1 replacement in metavinculin results in a new five-
helix bundle (that is comprised of a-helices H19 and H2–H5;
residues 959–1,130) that closely mimics the five-helix bundle
found in Vt (comprised of a-helices H1–H5; residues 891–1,062),
Figure 1. A Helix replacement mechanism is manifest in metavinculin. A: Structure based sequence alignment of a-helices H1 (underlined;
grey background) and H19 (underlined; pink background) and their preceding extended coil regions (underlined, bold, italicized). Residues 896–911
comprising a-helix H1 in human vinculin (Vt) show 56% identity to residues 964–979 comprising a-helix H19 in metavinculin (MVt). Identical residues
in MVt and Vt are indicated by an asterisk in the MVt sequence. B: Superposition of the metavinculin structure (residues 947–983; cyan) onto the
vinculin tail (Vt) structure (residues 879–915; PDB entry 1rkE). The a-helices of Vt are colored in red (H1; residues 896–911), orange (H2; residues 918–
937), yellow (H3; residues 944–972), green (H4; residues 975–1,005), and blue (H5; residues 1,014–1,046). An additional helix is seen in residues 850–
854 in the proline-rich region of metavinculin, before the disordered region (residues 860–946), which is indicated by five dots. Some residues of
metavinculin are labeled. The metavinculin extended coil is shown in ball-and-stick representation. C: Superposition of our full-length metavinculin
structure (cyan) onto the vinculin tail structure (Vt, magenta; residues 879–1,066) showing the conformations of the distinct residues of the extended
coil that precede a-helices H1 and H19, respectively, in the two structures.
doi:10.1371/journal.pone.0010679.g001
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equivalent Ca positions). Thus, the true helical bundle MVt
domain (residues 959–1,134) lacks the H1 a-helix of vinculin.
Recombinant four-helix H2–H5 protein was insoluble (ESR
personal communication), which precluded a direct comparison of
the binding of H1 versus H19 to the H2–H5 helix bundle by
conventional binding assays. However, a comparison of the tail
domain structures of metavinculin with that of vinculin demon-
strated that a-helix H19 has several additional interactions with the
four-helix bundle H2–H5 compared to a-helix H1 (Supplemen-
tary Figure S3). Specifically, there are two additional hydrophobic
and hydrogen bond interactions in metavinculin, and there is also
an electrostatic interaction of Arg-1107 with Glu-976 present in a-
helix H19, whereas the corresponding residues in Vt do not
interact (Supplementary Figure S3). Further, the MVt five-helix
bundle (a-helices H19, H2–H5; residues 959–1130; MVt-DH1) has
a significantly higher thermal melting temperature (72uC versus
67uC; Supplementary Figure S4) compared to the Vt five-helix
bundle (a-helices H1, H2–H5; residues 891–1066; coined DN-Vt
[lacking the extended amino-terminal extended coil of Vt])
consistent with the additional interactions directed by H19 versus
H1 seen in our crystal structures.
By contrast, the extended coil in metavinculin engages in fewer
interactions with the metavinculin five-helix bundle compared to
the distinct extended coil in Vt (Supplementary Figure S5, S6);
indeed, this region is disordered in one metavinculin molecule in
the asymmetric unit. The N-terminus of Vt affects binding to
acidic phospholipids [22] and MVt is impaired in binding to acidic
phospholipids [5]. The metavinculin structures now show that this
region is distinct in the two vinculin isoforms, thus explaining their
distinct PIP2 binding behaviors.
Structures of metavinculin mutations associated with
cardiomyopathies
Our full-length metavinculin crystal structure revealed that the
severity of the autosomal dominant mutations in metavinculin
identified in familial and sporadic HCM and DCM correlates with
their location. The least severe Ala934Val substitution mutation
resides on the displaced, disordered loop region that includes the
proline-rich region, Leu-954 lies on the MVt extended coil, and
the most severe mutation, Arg975Trp, resides on the unique H19
a-helix of metavinculin (Figure 2A).
To define the effect of these HCM and DCM mutations on
metavinculin structure, we determined the full-length crystal
structure of the DLeu954 DCM deletion mutant (Figure 2B).
Overall, the structure of full-length DLeu954-metavinculin
resembles that of metavinculin, where superposition of the two
full-length structures resulted in an r.m.s.d. of 0.54 A ˚ for 1,031 Ca-
atoms. Importantly, loss of Leu-954 results in a distinct
conformation of the extended coil that precedes a-helix H19
(Figure 2B) and this directs unique intramolecular interactions
(Supplementary Figure S7).
The HCM/DCM mutant Arg975Trp has profound effects on
the binding of metavinculin to actin [7], indicating that this
mutation, which is positioned within a-helix H19, should have
substantial consequences on metavinculin structure. Indeed,
recombinant full-length Arg975Trp metavinculin protein and its
tail domain was prone to aggregation and degradation (ESR
personal communication) precluding its structure determination.
However, we modeled this mutation based on our native
metavinculin structures (Figure 2C). In the metavinculin structure
a-helix H19 harboring Arg-975 is proximal to another helix
(residues 492–505) from the Vh3 domain present in the globular
head, where Arg-975 is involved in electrostatic interactions with
Table 1. Data reduction statistics.
Metavinculin DLeu954 MVt-DH1
Space group P43212 P43212 R3
Unit cell dimensions
a=b 170.9 A ˚ 171.1 A ˚ 62.44 A ˚
c 210.9 A ˚ 211.8 A ˚ 62.44 A ˚
a=b=c 90u 90u 111.87u
Resolution 50 A ˚–3.6 A ˚ 50 A ˚–3.4 A ˚ 50 A ˚–2.2 A ˚
Last shell 3.73 A ˚–3.6 A ˚ 3.52 A ˚–3.4 A ˚ 2.28 A ˚–2.2 A ˚
Total measurements 207,478 209,453 22,289
Unique reflections 36,379 42,424 11,090
Last shell 3,587 4,242 1,054
Wavelength 1 A ˚ 0.97929 A ˚ 0.97929 A ˚
Rsym
a 0.083 0.053 0.087
Last shell 0.671 0.373 0.435
I/s(I) 10.2 11.1 7.9
Last shell 2.9 4.3 1.9
Completeness 0.989 0.968 0.987
Last shell 0.994 0.986 0.947
Redundancy 5.7 5.0 2.1












Ii hkl ðÞ .
doi:10.1371/journal.pone.0010679.t001
Table 2. Crystallographic refinement statistics.
Metavinculin DLeu954 MVt-DH1
Resolution 50 A ˚–3.6 A ˚ 50 A ˚–3.4 A ˚ 50 A ˚–2.2 A ˚
Last shell 3.7 A ˚–3.6 A ˚ 3.5 A ˚–3.4 A ˚ 2.26 A ˚–2.2 A ˚
No. of reflections (working set) 34,508 40,136 10,411
No. of reflections (test set) 1,816 2,116 522
Rcryst
a 0.226 0.237 0.198
Last shell 0.289 0.286 0.239
Rfree
b 0.255 0.269 0.258
Last shell 0.288 0.332 0.318
No. of amino acid residues 2,048 2,044 163
No. of solvent molecules 95
Average B-factor
Protein 136.64 A ˚2 125.89 A ˚2 29.34 A ˚2
Solvent 39.43 A ˚2
R.m.s.d. from ideal geometry:
Bond lengths 0.009 A ˚ 0.009 A ˚ 0.012 A ˚








DFobs hkl ðÞ D
Where ,|Fcalc|. is the expectation of |Fcalc| under the error model used in
maximum-likelihood refinement.
bThe free R-factor is a cross-validation residual calculated by using 5% of
reflections which were randomly chosen and excluded from the refinement.
doi:10.1371/journal.pone.0010679.t002
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unit. Additionally, the side chain of Arg-975 lies close to the side
chain of Arg-502, allowing a possible hydrophobic stacking
interaction in the Arg975Trp mutant. Notably, the electrostatic
interaction of Arg-975 with Asp-505 is disabled by the introduc-
tion of the large hydrophobic side chain from tryptophan in the
Arg975Trp HCM/DCM metavinculin mutant.
Helix replacement does not affect the head:tail
interaction
The structure of full-length metavinculin also established that a-
helix H19 contributes to the VH-MVt interactions that clamp
metavinculin in its inactive conformation [17,22] (Supplementary
Figure S3B, S3C). While residues that direct the interactions of the
Vh1 head domain with MVt are identical to those used in the
Vh1:Vt interaction in vinculin, differences are found in the H1
versus H19 interaction with the Vh3 domain of VH. Specifically,
Arg-502 of the Vh3 domain interacts with Gln-904 on the vinculin
a-helix H1 but with Ser-972 on the metavinculin a-helix H19.
Additionally, in metavinculin Arg-975 of a-helix H19 interacts
with Asp-505 of Vh3. Indeed, native gel analyses showed that MVt
has a higher affinity for VH than that of the cardiomyopathy MVt-
Arg975Trp mutant (Supplementary Figure S8A) in agreement
with our modeling (Figure 2C). The effects were not evident in
competition analyses with the cardiomyopahty-associated mutant
MVt-DLeu954 (Supplementary Figure S8B), again in agreement
with our structural analysis (Figure 2B). Nonetheless, the H19 a-
helix and its extended coil of metavinculin do not affect the overall
interaction of native MVt for VH in solution, as MVt or Vt are
equally capable of displacing each other from pre-existing
complexes with VH (Supplementary Figure S8C).
Metavinculin a-helix H1 is dispensable for actin binding
Vinculin activation is required for binding to F-actin, which is
mediated by the Vt domain [23]. The MVt structure, where a-
helix H19 replaces H1 to mimic Vt, suggested that a-helix H1 was
dispensable for actin binding by metavinculin. Indeed, actin co-
sedimentation assays demonstrated that MVt-DH1 and metavin-
culin-DH1 can bind to F-actin (Figure 3A, 3C) and that
metavinculin-DH1 binding was, as expected, greatly augmented
by talin-VBS3 (Figure 3B, 3C), a known activator of vinculin [24].
Thus, the novel five-helix bundle tail domain of metavinculin
indeed directs actin binding.
Metavinculin a-helix H1 directs differential actin
organizing functions
To address whether the disordered a-helix H1 played important
roles in the unique actin bundling properties of metavinculin we
assessed the effects of deleting a-helix H1 on actin filament
organization. Fluorescence microscopy of TRITC-phalloidin
labeled F-actin demonstrated that, as expected [7,12], Vt induced
actin bundles whereas MVt induced a meshwork of actin filaments
(Figure 3D). Notably, deletion of a-helix H1 from MVt converted
this into a vinculin-like molecule that induced actin bundles
(Figure 3D). Similar effects were seen in low speed actin bundling
experiments where MVt-DH1 displays similar bundling effect as
Vt (Figure 3E). Thus, the displaced H1 a-helix directs the
differential actin organizing functions of metavinculin.
The H19 a-helix of metavinculin impairs
homodimerization
Vinculin oligomerization effectively amplifies its interactions
with other binding partners to stabilize adhesion junctions [25,26].
Vt readily dimerizes and trimerizes in the presence of the acidic
phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2), where-
as MVt fails to form homodimers but does heterodimerize with Vt
[5]. Our metavinculin structures suggested that the H19 a-helix
and its preceding extended coil might impair oligomerization of
metavinculin. Indeed, full-length metavinculin lacking that H19 a-
helix (metavinculin-DH19), as well as metavinculin lacking both
H19 and H1 a-helices (metavinculin-DH1DH19) readily form
homodimers in solution independent of PIP2 (Figure 4A; Supple-
Figure 2. Crystal structure of the metavinculin-DLeu954 cardiomyopathy mutant. A: Native full-length metavinculin crystal structure
showing the location of the three recurrent, autosomal dominant mutations, Ala934Val, DLeu-954, and Arg975Trp, that have been identified in
familial and sporadic HCM and DCM. Arg975 and Leu954 are shown in space filling representation. B: Superposition of the native and metavinculin-
DLeu954 crystal structure showing the differential extended coil formations (native, green; mutant, blue) and distinct interactions with the five-helix
bundle tail domain. Electrostatic surface potential of ,220 to .+20 kbT, where kb is the Boltzmann constant and T is the temperature (red, negative;
blue, positive) is shown for the remainder of the tail domain which is close to identical for the two structures in the region shown. C: Modeling of the
Arg975Trp mutation suggests that contacts found in the native metavinculin structure of the H19 a-helix with the Vh3 seven-helix bundle (in
particular eletrostatic interactions with Asp505) are lost in this severe HCM/DCM mutant.
doi:10.1371/journal.pone.0010679.g002
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PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10679Figure 3. a-helix H1 directs the unique actin organizing properties of metavinculin. A: Vt (lanes 3, 4), MVt (lanes 5, 6), or MVt-DH1 (lanes 7,
8) or full-length B: inactive or C: talin-VBS3 activated vinculin (lanes 1, 2), metavinculin (lanes 3, 4), or MV-DH1 (lanes 5, 6) were tested for their ability
to co-sediment F-actin (S, supernatant; P, pellet). Note that following activation by binding with talin-VBS3 (C), there is a substantial increase in the
proportion of F-actin that is bound by vinculin, metavinculin and metavinculin-DH1 (B), and that there is no difference in binding to F-actin for MV-
DH1 compared to metavinculin or vinculin. Therefore, a-helix H1 is dispensable for metavinculin binding to F-actin, which is functionally and
structurally replaced by metavinculin a-helix H19. The three vinculin proteins (vinculin, metavinculin, and MV-DH1) are indicated as ‘(M)V’. D:
Fluorescence microscopy analyses of TRITC-phalloidin labeled F-actin alone, or when incubated with 0.2 mM MVt, Vt, or MVt-DH1. Note that loss of a-
helix H1 from MVt converts this into a vinculin-like molecule that provokes the formation of tight actin bundles, whereas MVt provokes a meshwork
of actin filaments. We obtained similar results with 0.4 mM tail domains (data not shown). The width of each individual panel corresponds to about
80 mm. E: F-actin bundling efficiency of Vt (left gel; lanes 5, 6), MVt (right gel; lanes 3, 4; asterisk) and MVt-DH1 (right gel; lanes 7, 8) were analyzed by
low speed centrifugation (S, supernatant; P, pellet). Vt on the left gel, which migrates slightly less than MVt-DH1, is not labeled. Control reactions
containing only F-actin (left gel; lanes 1, 2), Vt (left gel; lanes 3, 4), MVt (right gel; lanes 1, 2), or MVt-DH1 (right gel; lanes 5, 6) were also run to show
that the proteins by themselves do not pellet under the experimental conditions. Representative experiment carried out in duplicate is shown.
doi:10.1371/journal.pone.0010679.g003
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DH1 are only found as monomers. Interestingly, deletion of either
or both of these a-helices did not affect heterodimerization with Vt
(Figure 4B–D). Therefore, the H19 a-helix impairs metavinculin
homodimerization but does not affect metavinculin:vinculin
interactions.
Discussion
The studies presented herein establish that an a-helix and
extended coil replacement mechanism controls metavinculin
structure, oligomerization, and F-actin bundling functions. The
helix replacement is directed by the unique intramolecular
interactions of the H19 a-helix and its preceding extended coil
of the metavinculin insert with the H2–H5 helical bundle present
in the tail domain, which replaces the H1 a-helix and its preceding
extended coil that are present in the five-helix bundle tail domain
of vinculin. Notably, this event explains many of the properties
ascribed to metavinculin, where we have shown that the
replacement of the H1 a-helix controls metavinculin’s unique
actin organizing properties and directs metavinculin oligomeriza-
tion. Finally, the importance of helix replacement is underscored
by the findings that recurrent and severe metavinculin mutations
found in cardiomyopathies are positioned within or immediately
preceding to the H19 a-helix and that the Arg975Trp mutation
affects the head:tail interaction.
The H19 a-helix restricts metavinculin oligomerization, as
deletion of this helix triggers the spontaneous formation of
metavinculin homodimers. Thus, one level of control of
metavinculin-vinculin heterodimerization with vinculin as seen in
muscle cells may involve the acidic phospholipid PIP2 and
vinculin, as PIP2 is thought to promote vinculin oligomerization
by unfurling the tail domain of activated vinculin [2], whereas
metavinculin has a reduced affinity for PIP2 relative to vinculin
Figure 4. a-Helix H19 impairs metavinculin homodimerization but not heterodimerization with vinculin. A: a-helix H19 impairs
metavinculin homodimerization. Native gel analyses of full-length metavinculin (MV, lane 1), metavinculin-DH1 (lane 2), metavinculin-DH19 (lanes 3
and 4), and metavinculin-DH1DH19 (lanes 5 and 6) are shown. Metavinculin and metavinculin-DH1 are monomers in solution, while metavinculin-
DH19 and metavinculin-DH1DH19 both form monomers and dimers as determined by sizing chromatography (Supplementary Figure S9). Peak
fractions for each species were run on this native gel (lanes 3–6). The identities of the two oligomeric species of metavinculin-DH19 and metavinculin-
DH1DH19 that were separated by gel filtration chromatography (lanes 3–6) were confirmed by western blot analyses (data not shown). B:
Vinculin:metavinculin interactions as analyzed by pull-down assay and SDS PAGE gel analyses. Purified GST-Vt was tested for its ability to bind to full-
length metavinculin (MV, lanes 2–4), metavinculin-DH1 (lanes 5–7), or metavinculin-DH19 (lanes 8–10) +/2 PIP2. Protein identity was confirmed by
Western blotting (data not shown): the band marked with an asterisk is a GST-Vt homodimer, which was also observed all other lanes where GST-Vt
and PIP2 is present (lanes 4, 7, and 10). No non-specific binding was observed of metavinculin to GST (lanes 2, 5, and 8). C: SDS-PAGE analysis of GST-
Vt interactions with MVt. Purified GST-Vt was tested for its ability to bind to MVt and Vh2–Vh3 (negative control) +/2 PIP2. As with the full-length
proteins (B), heterodimerization is observed of GST-Vt with MVt (lane 6) and MVt-DH1 (lane 8) but not with the Vh2–Vh3 domains (lanes 3, 4). D: The
His-tag Western blot (top panel; 1 min exposure time) shows no non-specific binding to Vh2–Vh3 but strong binding to MVt (lane 6) and MVt-DH1
(lane 8) in the presence of PIP2. The GST Western blot (bottom panel; 3 min exposure time) shows GST-Vt presence in all lanes.
doi:10.1371/journal.pone.0010679.g004
Metavinculin Crystal Structure
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10679[5]. Although what region of vinculin’s tail domain binds to PIP2 is
still not resolved [2,22,27,28,29,30], PIP2 does bind to Vt variants
that perturb interactions between the extended coil with the five-
helix bundle more readily than to intact Vt [22]. This suggests that
regions that are distinct in the two crystal structures of MVt and
Vt harbor the PIP2 binding site, which may explain the impaired
binding of PIP2 to MVt [22]. Collectively, we posit that PIP2
binding may promote metavinculin:vinculin heterodimer forma-
tion by unfurling Vt [2] and allowing the Vt interaction with MVt
(Figure 5). A portion of MVt can likely unfurl without PIP2 in
solution, as the extended coil that precedes H19 is disordered in
one molecule of the metavinculin crystal structure. However,
further unfurling of MVt might be blocked by its distinct a-helix
H19, which we posit impairs PIP2 binding and which appears to
have a higher affinity for the H2–H5 four-helix bundle than the a-
helix H1 in vinculin. Such a scenario would explain why
metavinculin does not self-oligomerize and why its interactions
are restricted to those with vinculin (Figure 5).
Muscle tissue homeostasis requires proper levels and function of
metavinculin, a fact underscored by the clinical association
between DCM and reduced levels of metavinculin [9] as well as
by the recurrent mutations in the metavinculin insert in HCM and
DCM [7,9]. Of the three recurrent mutations Arg975Trp is
located on the H19 a-helix, and helix replacement is necessary to
impart the unique actin bundling properties of metavinculin,
which requires the replaced H1 a-helix (Figure 3C). Similarly,
Leu-954 resides on the extended coil that precedes H19 in
metavinculin. The Arg975Trp mutation introduces a large
hydrophobic patch in H19 a-helix, whereas loss of Leu-954
provokes a distinct conformation of the extended coil. These
findings establish that critical structural features of this subdomain
orchestrate the actin network in a fashion required for muscle cell
homeostasis.
Materials and Methods
Analysis of melting temperature by circular dichroism
(CD), Head-tail displacement assays, Dynamic light
scattering (DLS) analysis
Details regarding CD, displacement assays, and DLS experi-
ments are all provided in the Supplementary Methods (Methods
S1).
Expression constructs for metavinculin and vinculin
proteins
Human metavinculin cDNA (gi|50593530) was generated by
PCR cloning the additional 68 residue (204 bp) insert, using long
oligonucleotides and our vinculin cDNA construct [17], and was
cloned into the pET3 expression vector (Novagen). The final
expression construct was a C-terminal octa-histidine (His8) fusion
tag and included all residues (1–1,134) of human metavinculin.
For biochemical studies, full-length human vinculin, metavin-
culin, and deletion mutants of metavinculin (metavinculin-DH1,
lacking residues 895–915; metavinculin-DH19, lacking residues
963–983; and metavinculin-DH1DH19, lacking residues 895–915
and 963–983) were cloned into a modified pET28 vector using
NdeI and NotI cloning sites to obtain a precision protease cleavable
N-terminal His8-tagged fusion constructs. For metavinculin-DH1,
the N-terminal (residues 1–894) and C-terminal (residues 916–
1,134) sequences were first amplified independently and the
resultant PCR products were subsequently used as a template for
amplification of the entire stretch using the N-terminal forward
primer and the C-terminal reverse primer to obtain metavinculin-
DH1 amplicons. A similar approach was used to clone
metavinculin-DH19, in which the N-terminal (residues 1–962)
and C-terminal (residues 984–1,134) segments were first amplified
and then used as templates to obtain metavinculin-DH19
amplicons. Metavinculin-DH1 was used as a template to obtain
metavinculin-DH1DH19 clones. All clones were transformed into
BL21-DE3 (Novagen) for expression of the His8-tagged fusion
proteins.
The full-length DCM metavinculin mutant DLeu954 was
cloned using traditional molecular biology techniques.
MVt-DH1 (residues 959–1,130) was cloned into a modified
pET28 vector using the NdeI and BamHI cloning sites, to obtain an
N-terminal His8-tagged fusion protein having a precision protease
cleavage site. The GST tagged vinculin tail domain (GST-Vt;
residues 879–1,066) was obtained by cloning Vt in pGEX-4T-1
(GE Healthcare) using the BamHI and EcoRI cloning sites. DN-Vt
(residues 891–1,066) was cloned into pGEX-6P-1 (GE Healthcare)
using BamHI and NotI cloning sites. In addition, Vt (residues 879–
1,066), MVt (residues 879–1,134), MVt-DLeu954 (residues 879–
1133), and MVt-R975W (residues 879–1134) were also cloned in
pET28, using NdeI and XhoI cloning sites, to obtain cleavable N-
terminal hexa-histidine tagged fusion constructs.
The head domain of vinculin (VH; residues 1–843) was cloned
into a modified pET3 vector using NcoI and NotI restriction sites to
obtain a precision protease cleavable C-terminal His8-tagged
fusion protein. The truncated head domain (Vh2–Vh3; residues
Figure 5. Helix and extended coil replacement control
metavinculin oligomerization. Binding of PIP2 is thought to
promote vinculin oligomerization through tail:tail interactions [25].
Metavinculin on the other hand does not bind to PIP2 nor
homodimerize [5] and our binding studies (Figure 4) show that
metavinculin interacts with Vt:PIP2. Further, our metavinculin crystal
structures (Figure 1) show that the N-terminus of Vt thought to be
involved in PIP2 binding [22] is distinct in metavinculin, thus explaining
why metavinculin does not bind to PIP2. Finally, metavinculin
heterodimerization does not require a-helices H1 or H19 (Figure 4)
suggesting that heterodimerization occurs via the metavinculin four-
helix (helices H2–H5) bundle. The vinculin head domain VH is shown in
gray, the distinct extended coils are represented by ‘‘,, ’’ (in black or
magenta for Vt or MVt, respectively) while the remainder of Vt or MVt is
shown in blue or red, respectively. For clarity, the disordered a-helix H1
of metavinculin is not shown.
doi:10.1371/journal.pone.0010679.g005
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NotI cloning sites to produce a precision protease cleavable N-
terminal His8-tagged fusion protein. The head domain containing
a-helix H1 of vinculin (VH-H1; residues 1–915) was cloned into
the pET-28 vector using NdeI and SalI restriction sites toD obtain a
thrombin cleavable N-terminal His6 tag. All constructs were
verified by sequencing.
Protein expression and purification
Expression of recombinant proteins (His8-tagged full-length
human metavinculin, metavinculin-DLeu954, VH, Vh2–Vh3,
MVt, MVt-DLeu954, MVt-R975W, Vt, GST-Vt, and GST-DN-
Vt) was performed by growing transformed BL21-DE3 cells at
37uC in Luria-Bertani medium containing appropriate antibiotics.
Protein expression was induced at OD600=0.8 with 0.5 mM
IPTG and cells were harvested after incubation at 30uC for 24 hr.
Pelleted cells of His-tagged full-length human metavinculin, re-
suspended in 20 mM Tris-HCl (pH 7) and 150 mM NaCl, was
lysed in presence of EDTA-free protease inhibitor cocktail (Roche)
by passing through French Pressure Cell (2 cycles) and clarified by
ultracentrifugation (100,0006g for 45 min). The cell lysate was
loaded on a HisTrap chelating nickel affinity column (GE
Healthcare) and washed extensively with 20 mM Tris-HCl and
150 mM NaCl (38 column volumes). The bound protein was then
eluted over a gradient of 0.5 M imidazole (pH 8) and pooled peak
fractions were dialyzed extensively against 25 mM CAPS (pH 10)
buffer. The dialyzed protein sample was further purified using ion-
exchange chromatography, by applying the sample on Hi-Trap
QHP column (GE Healthcare) pre-equilibrated in 25 mM CAPS
(pH 10) buffer. The bound protein was eluted using a salt gradient
of up to 1 M NaCl in 25 mM CAPS (pH 10) and, following
concentration, the protein was loaded onto a preparative Super-
dex-200 26/60 column (GE Healthcare) pre-equilibrated in
20 mM Tris (pH 8) and 150 mM NaCl. Purified metavinculin
protein was then buffer exchanged to 10 mM Tris (pH 8) and
1 mM DTT and concentrated to 22 mg/ml for crystallization.
Similar expression and purification protocols were employed for
purifying the metavinculin-DLeu954 and the His8-tagged truncat-
ed mutants metavinculin-DH1, metavinculin-DH19, and metavin-
culin-DH1DH19. The purified protein of metavinculin-DLeu954
was concentrated to 22 mg/ml in the final buffer containing
10 mM Tris (pH 8) and 1mM DTT and the metavinculin-DH1,
metavinculin-DH19, and metavinculin-DH1DH19 proteins were
concentrated to 9.5, 6.8, and 2.6 mg/ml respectively, in 20 mM
Tris (pH 8) and 150 mM NaCl.
For the production of selenomethionine (SeMet)-labeled full-
length metavinculin, the metavinculin expression plasmid was
transformed into B834 methionine auxotroph cells and grown
overnight at 37uC in Luria-Bertani medium (containing 20 mg/l
ampicillin). The cells were separated by centrifugation at 3,0006g
for 20 min, washed twice with sterile M9 minimal media and
inoculated into pre-formulated SeMet media (Molecular Dimen-
sions Ltd.) and incubated for 4 hr at 37uC. Protein production was
induced with 0.5 M IPTG and cells were harvested after 24 hr
incubation at 30uC. The purification of SeMet-labeled metavin-
culin was similar to wild type full-length metavinculin. The protein
was concentrated to 22 mg/ml in 10 mM Tris (pH 8) and 1 mM
DTT and used for crystallization.
Pelleted cells (VH, VH-H1, MVt, MVt-DLeu954, MVt-
R975W, or Vt) were re-suspended and lysed by sonication in
100 ml of 50 mM NaH2PO4 (pH 8), 300 mM NaCl, and 5 mM
imidazole. The lysate was then clarified by ultracentrifugation
(100,0006g for 45 min) and the supernatant applied to HisTrap
chelating nickel affinity column (GE Healthcare) and washed
extensively with sonication buffer (22 column volumes). The
bound protein was then eluted over a gradient of 1 M imidazole
(pH 8). Affinity tags were removed by overnight cleavage with
thrombin (VH-H1, MVt, MVt-DLeu954, MVt-R975W, or Vt) or
precision protease (MVt-DLeu954 and MVt-R975W) at 4uC, and
all proteins were further purified by gel filtration using a Superdex-
200 (VH or VH-H1) or Superdex-75 (MVt, MVt-DLeu954, MVt-
R975W, or Vt) column (GE Healthcare) pre-equilibrated in
20 mM Tris-HCl (pH 8) and 150 mM NaCl.
MVt-DH1 was produced using 500 ml of auto-induction media
grown at 30uC for 20 hr in presence of 40 mg/l of kanamycin
[31]. The cell pellet was re-suspended in 20 mM Tris-HCl,
200 mM NaCl and 5 mM Imidazole (pH 8) and lysed by
sonication. Following clarification by ultracentrifugation
(100,0006g for 45 min), the cell lysate was applied on HisTrap
chelating nickel affinity column (GE Healthcare). After extensive
washing (20 column volumes) in the lysis buffer, bound His-tagged
MVt-DH1 was eluted over a gradient of 0.5 M imidazole (pH 8) in
20 mM Tris-HCl (pH 8) and 200 mM NaCl. Following elution,
the His8 tag was removed by overnight treatment with precision
protease at 4uC and the concentrated MVt-DH1 sample was
further purified using a Superdex-75 column (GE Healthcare),
pre-equilibrated with 20 mM Tris (pH 8) and 400 mM NaCl. The
purified protein was concentrated to 11 mg/ml in the final buffer
of 20 mM Tris-HCl (pH 8) and 400 mM NaCl.
Vh2–Vh3 was purified similar to MVt-DH1, however the His8
tag was not removed and the size exclusion chromatography on a
Superdex-75 column was carried out using 20 mM Tris-HCl
(pH 8) and 150 mM NaCl. The purified protein (6.6 mg/ml) was
used for biochemical studies.
For GST-Vt purification, the cell pellet was re-suspended in
20 mM Tris-HCl (pH 8) and 150 mM NaCl, lysed by sonication
and clarified by ultracentrifugation (100,0006g for 45 min).
Subsequently, the supernatant was applied onto GSTrap FF
column and after extensive washing with the buffer (20 mM Tris-
HCl (pH 8) and 150 mM NaCl) the bound GST-Vt was eluted
with 20 mM reduced glutathione (pH 8). The eluted protein was
further purified on a 26/60 Superdex 75 column that was pre-
equilibrated with 20 mM Tris-HCl (pH 8) and 150 mM NaCl and
was used for all biochemical studies at a concentration of 1.8 mg/
ml.
DN-Vt was purified by affinity chromatography on GST-
Sepharose similar to GST-Vt. Following elution, GST-DN-Vt was
incubated with precision protease overnight at 4uC in the presence
of 20 mM Tris-HCl (pH 8), 400 mM NaCl, 1 mM DTT, and
1 mM EDTA. After concentration, the cleaved protein was
purified on a 26/60 Superdex 75 column (GE Healthcare), pre-
equilibrated with 20 mM Tris-HCl (pH 8), 400 mM NaCl, 1 mM
DTT, and 1 mM EDTA to obtain purified DN-Vt. The protein
was concentrated to 9.7 mg/ml for CD experiments.
Crystallization and X-ray data collection
The Hauptman-Woodward High Throughput Crystallization
Facility identified several similarly shaped full-length human
metavinculin crystals from comparable conditions. After extensive
optimization, these crystals grew up to 0.4 mm
3 over a period of
several weeks. Despite significant efforts to improve these
metavinculin crystals, diffraction was highly mosaic, to at best
8A ˚ Bragg spacings. Systematic screening of hundreds of crystals at
the Advanced Photon Source (APS) at Argonne National
Laboratory (ANL) beamlines (SBC-CAT ID and SER-CAT)
resulted in one complete native data set to 4.2 A ˚ resolution. SDS-
PAGE gel analysis of these crystals showed that some degradation
occurred during crystal growth over several weeks at room
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within a few days, as soon as their size reached 0.1 mm
3–0.2 mm
3.
A few of these smaller sized crystals, produced by hanging drop
vapor diffusion using a reservoir solution of 0.6 M Na/K
phosphate and 175 mM ammonium sulfate, diffracted X-rays to
3.6 A ˚ Bragg spacings at APS-ANL with much improved spot
shape. The native metavinculin crystallization conditions were also
used for the SeMet metavinculin and metavinculin-DLeu954 and
the latter crystals were streak seeded to obtain a 3.4 A ˚ data set at
the APS-ANL SER-CAT 22ID beam line. Native and mutant
metavinculin crystals belong to the tetrahedral space group
P43212, with unit cell dimensions a=b=171.5 A ˚ and
c=211.4 A ˚ and two molecules in the asymmetric unit (Z=16), a
volume to mass ratio, VM [32], of 3.13 A ˚ 3/Da, and a solvent
content of about 60%. The data collection statistics are provided
in Table 1.
All images were integrated, scaled, and merged using HKL2000
[33]. SeMet-metavinculin data sets were also collected to 4.4 A ˚
Bragg spacings at the peak of the Se K absorption spectrum. Full-
length human metavinculin crystals were extremely sensitive to
radiation, especially at the Se peak wavelength. An attenuation of
75% (corresponding to 25% transmission) and 5 seconds exposure
time allowed complete data set collection from a single crystal.
MVt-DH1 crystals were obtained by sitting drop vapor diffusion
from 2.5 M NaCl and 100 mM sodium acetate (pH 4.5). Crystals
of size less than 50 microns were obtained within 36 hr and
appeared as needle clusters. A single crystal was dissected from the
cluster, flash frozen directly in liquid nitrogen after a brief transfer
into a cryo-protection solution containing reservoir solution
supplemented with 35% (v/v) glycerol. Crystals of MVt-DH1
belong to rhombohedral space group R3, with unit cell dimensions
a=b=c=62.4 A ˚ and a=b=c=111.9u and one molecule in the
asymmetric unit (Z=9) with a volume to mass ratio, VM [32], of
2.9 A ˚ 3/Da corresponding to a solvent content of about 57%. X-
ray diffraction data were collected at the APS SBC-CAT 19ID
beam line and processed using HKL3000 [34]. The data
collection statistics are provided in Table 1.
Structure determination and crystallographic refinement
We obtained the initial phases for metavinculin from our
original 4.2 A ˚ native data set by molecular replacement using full-
length vinculin (PDB entry 1tr2) [17] as the search model in the
program MOLREP [35]. However, crystallographic refinement
was stalled due to model bias at this resolution. Experimental
phases obtained from a 4.4 A ˚ SeMet metavinculin data set allowed
us to overcome over fitting. Of the 76 Se in the asymmetric unit,
60 were identified by anomalous difference Fourier calculation
and were further validated using the program SHARP [36]. The
resulting experimental map was used to model the C-terminal tail
domain of metavinculin and Se sites were used to discern the N-
terminal helix identity of the tail domain. The Se sites allowed us
to rule in or out possible rearrangements of the helical bundles.
Indeed, Vt has three methionines in its H1 a-helix and none in its
N-terminal strand, while MVt has one methionine in its N-terminal
strand but none it in its H19 a-helix, which is positioned in the H1
binding site of Vt. Thus, the experimental phases provided an
unbiased map that suggested that instead of an insertion of a
domain at residue 915, the metavinculin insert replaces vinculin a-
helix H1 with a-helix H19 from the insert. Crystallographic
refinement was carried out using the 3.6 A ˚ native data set. After
several rounds of model building into both molecules in the
asymmetric unit, the NCS operators were refined sufficiently to
provide an average map that showed a high level of side chain
detail and, together with the Se positions and our high resolution
MVt-DH1 structure, allowed unambiguous tracing. Low resolu-
tion as well as variable domain movement between the two
subunits in the asymmetric unit were limiting factors in applying
non-crystallographic symmetry based refinement using REFMAC
[35]. Thus, autoBUSTER was used in the final rounds of
refinement, after each cycle of manual model building, where
non-crystallography symmetry restraints were applied through
implementing local structure similarity restrains (LSSR) [37,38]
along with application of group B-factor for individual residues.
Omit maps, calculated using SFCHECK [39], and B-factor
sharpened maps were used to achieve better tracing of the main
chain as well as some of the side chains. However, at this
resolution disordered regions were difficult to parameterize in
terms of multiple conformations, which limited the scope of
reliably assigning bound water molecules. Remarkable improve-
ment in the model quality was achieved by refinement with
autoBUSTER through implementation of local structure similarity
restraints (LSSR) [38] and manual building using Coot [40]. The
refinement statistics for metavinculin are provided in Table 2.
The full-length metavinculin structure was used as a search
model to solve the structure of metavinculin-DLeu954 by
molecular replacement using the program MOLREP [35]. Rigid
body refinement was followed by restrained refinement with
REFMAC5 [35]. Subsequently, all refinement was carried out
using autoBUSTER by specific implementation of LSSR [38] and
manual model building was achieved with Coot [40]. The
refinement statistics for metavinculin-DLeu954 are provided in
Table 2.
The final structures of metavinculin and metavinculin-DLeu954
contained residues 1–834, 954–1,114 and 1,122–1,130 in subunit
A and residues 1–859 and 947–1,130 in subunit B. Due to lack of
electron density and disordered nature, the residues 835–953,
1,115–1,121, 1,131–1,134 in subunit A and residues 860–946 and
1,131–1,134 in subunit B were not included in the final model.
The structure of MVt-DH1 was solved by molecular replace-
ment using the Vt domain of Vh:Vt complex (PDB entry 1rke)
[19] as the search model in the program MOLREP [35]. Rigid
body refinement was followed by iteration of restrained refinement
with REFMAC5 [35] and manual model building into 2Fobs-Fcalc
maps using Coot [40]. The final refined model comprises residues
960–1,116 and 1,122–1,130. Due to poor electron density, the
region encompassing residues 959 and 1,117–1,121 were not
included in the final model. The refinement statistics for MVt-
DH1 are provided in Table 2.
Actin binding and bundling analyses
Actin pull-down assays were carried out as described [24] either
in PBS or in 20 mM Tris-HCl (pH 8) and 150 mM NaCl. Briefly,
30 mM of freshly polymerized F-actin was incubated at room
temperature for 20 min with 60 mM each of the tail domains of
vinculin (Vt) and metavinculin (MVt and MVt-DH1). Subse-
quently, after ultracentrifugation at 95,0006ga t2 5 uC for 15 min,
the supernatant and the pellet were analyzed on SDS-polyacryl-
amide gels and the protein bands visualized by staining with
Coomassie Blue. Similarly, actin binding experiments were carried
out for inactive and active full-length vinculin (15 mM), metavin-
culin (14 mM), or MV-DH1 (15 mM) with F-actin (30 mM).
Activation of full-length vinculin or metavinculin was achieved
by incubating the proteins with 20-fold molar excess of talin-VBS3
peptide at room temperature for 10 min prior to mixing with F-
actin.
Actin bundling analysis using fluorescence microscopy was
performed using F-actin labeled with TRITC-phalloidin as
described [41]. Skeletal muscle actin (Cytoskeleton) in G-actin
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0.2 mM CaCl2) was allowed to polymerize at a concentration of
1 mg/ml in F-actin buffer (1 mM imidazole pH 7.4, 1 mM ATP,
0.1 M KCl, and 2 mM MgCl2) for 1 hr at 37uC. Labeling of F-
actin was performed by incubating 500 ml of F-actin buffer with
20 ml of polymerized F-actin (0.8 mM final actin concentration)
and 10 ml of TRITC-phalloidin (0.1 mg/ml stock in DMSO) for
2 hr on ice. The effect of various vinculin and metavinculin tail
domains on F-actin was investigated by mixing half volumes (0.5:1)
of the target proteins (0.2 mM final concentration) with TRITC-
phalloidin labeled F-actin (0.4 mM final actin concentration) and
incubating at 37uC for 1 hr. Aliquots of the mixture were then
placed on a parafilm and covered with poly-L-lysine coated glass
cover slip (Fisher Scientific) and incubated further for 1 hr at 4uC.
The adsorbed protein on the cover slip was fixed with 3.7%
formaldehyde for 20 min and mounted after washing thrice with
PBS. The fluorescent images of F-actin were recorded with an
Olympus FluoView 1,000 Confocal Microscope and processed
using FV10-ASW software (Olympus).
All F-actin bundling analyses using low speed centrifugation was
carried out using freshly polymerized F-actin. Briefly, actin
(purchased from Cytoskeleton Inc, CO, USA) was polymerized
in F-actin buffer (20 mM Tris-HCl pH 8, 10 mM MgCl2,1 0m M
ATP, 0.2 mM CaCl2 and 0.1 M KCl) at 5 mg/ml for 30 min at
room temperature and precisely after the incubation time the F-
actin solution is further diluted with equal volume of PBS to obtain
F-actin at a final concentration of 2.5 mg/ml. F-actin solution was
then spun at 7,500 r.p.m. for 10 min and the supernatant is used
immediately for sedimentation assays. The above procedure for
preparation of F-actin seems to be critical as any deviation tend to
produce more F-actin in the pellets including that of the control
experiment. Bundling analyses were carried out using 30 mMF -
actin (optimal concentration required to see bundling effect) with
equimolar concentration of the tail domains. The tail domains (Vt,
MVt or MVt-DH1) were incubated with or without F-actin at
room temperature for 10 min and centrifuged at low speed (6,000
r.p.m.; Eppendroff table top centrifuge) for 10 min. The superna-
tant was removed without disturbing the pellet and stored
separately while the pellet was washed gently by layering with
100 ml of PBS and removing the excess buffer. The last step was
repeated gently three more times without disturbing the pellet and
subsequently, the supernatant and pellet were analyzed on SDS-
polyacrylamide PHAST gels and protein bands visualized with
Coomassie blue staining.
GST pull-down dimerization analyses
One ml of purified GST-Vt (0.5 mM; 20 mM Tris-HCl,
150 mM NaCl) was incubated with 40 ml of GST-Sepharose
beads on a rotary shaker at room temperature for 30 min. Beads
were then washed three times with 1 ml buffer containing 20 mM
Tris-HCl pH 8 and 150 mM NaCl to eliminate any trace amounts
of unbound GST-Vt. In one set of experiments, bound GST-Vt
was then further incubated with 10-fold molar excess (5 mM) of
phosphatidylinositol-4,5-bisphoshpate (PIP2)a t3 7 uC for 1 hr.
PIP2 solution (choloroform:methanol:water ratios of 20:9:1) as
obtained from the manufacturer (Avanti Polar Lipids, Inc.) was
vacuum dried and re-suspended in 20 mM Tris-HCl (pH 8) and
150 mM NaCl to a final concentration of 5 mg/ml. Prior to the
experiment, the PIP2 solution was incubated at 42uC for 2 hr and
diluted to the final concentration in the reaction mixture. The final
concentration of PIP2 (5 mM) used in the reaction was well below
the measured CMC value [42]. Following incubation beads were
subjected to extensive washing (three cycles of 1 ml each) with the
buffer to remove excess PIP2. In the second set of experiments,
GST-Vt was used directly for the binding experiment to compare
the binding efficiency of metavinculin in the absence of PIP2.
Subsequently, 15 mM of ‘‘pre-activated’’ (using talin-VBS3) His8-
tagged metavinculin or metavinculin deletion mutants were
incubated with either PIP2-treated or untreated GST-Vt for 1 hr
at 37uC. The beads were then washed three times with 1 ml buffer
and GST-Vt bound metavinculin heterodimer was eluted in 20 ml
of 20 mM Tris-HCl and 150 mM NaCl containing 20 mM
reduced glutathione and analyzed by SDS-PAGE. Similarly,
formation of GST-Vt heterodimer with MVt was also analyzed
using a truncated vinculin head domain (Vh2–Vh3) as a negative
control. Proteins were identified by Western blot analysis using
HRP-conjugated aHis or aGST antibodies.
Supporting Information
Methods S1 Supplementary Methods.
Found at: doi:10.1371/journal.pone.0010679.s001 (0.03 MB
DOC)
Figure S1 Helix replacement mechanism in metavinculin.
Structure-based sequence alignment of the a-helices of vinculin
(Vt) and metavinculin (MVt) tail domains aligns the Vt a-helix H1
with the MVt a-helix H19 and their respective N-terminal
extended coils. This was a surprising revelation from the crystal
structure since it was assumed that the a-helix H1 that is identical
in sequence in the two isoforms would also be structurally
conserved. The a-helices of MVt are underlined and colored in
grey (H19), red (H1), orange (H2), yellow (H3), green (H4), and
blue (H5). The structurally equivalent extended coil regions are in
bold, underlined, and italicized. The Vt extended coil region
(residues 879–888) is underlined in the MVt sequence. Identical
residues in MVt and Vt are indicated by an asterisk in the Vt
sequence.
Found at: doi:10.1371/journal.pone.0010679.s002 (3.44 MB TIF)
Figure S2 MVt electron density map. Stereo view of the final
2Fobs-Fcalc electron density map at 2.2 A ˚ of the metavinculin tail
domain contoured at 1s around the replaced a-helix H19
represented in sticks. The remaining four a-helices are shown as
a cartoon. The a-helices of MVt are colored in orange (H2;
residues 986–1,004), yellow (H3; residues 1,012–1,038), green (H4;
residues 1,043–1,071), and blue (H5; residues 1,081–1,114) while
the a-helix H19 (residues 964–979) is shown in sticks.
Found at: doi:10.1371/journal.pone.0010679.s003 (2.52 MB TIF)
Figure S3 Intramolecular interactions of a-helices H1 in
vinculin versus H19 in metavinculin. Schematic of the intramo-
lecular interactions of a-helix H1 of Vt (A) versus those of a-helix
H19 of MVt (B). The residues binding to Vt a-helix H1 (boxed in
pale blue) or MVt a-helix H19 (boxed in peach) are shown on the
left (A) or on the right (B) of the respective helices. Residues are
distinguished according to the type of their interaction (hydro-
phobic, white; hydrogen bonds, gray; backbone hydrogen bonds,
blue; electrostatic interactions, pink). The asterisks indicate
additional interactions found in MVt (Ser-1002, Arg-1006, Arg-
1107) or altered interactions compared to Vt (Ser-972 with Lys-
1103 in MVt versus Gln-904 with Lys-1035 in Vt). C: Cartoon
stereo drawing of the full-length metavinculin crystal structure.
The head domain, VH, is shown in pink (Vh1 sub-domain;
residues 1–258) and gray (residues 259–840) and the tail domain,
MVt, is shown in blue (residues 946–963 and 980–1,132) and
yellow (a-Helix H19; residues 964–979). a-Helix H19 is shown in
yellow and is not involved in the Vh1:MVt interaction. The
vinculin and metavinculin structure, including the distinct a-
helices H1 and H19, superimpose well (as shown in the
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vinculin is also not involved in the Vh1:Vt interface. The entire
head domain (residues 1–843) of metavinculin shows a root mean
square deviation (r.m.s.d.) of 1.57 A ˚ for 575 Ca atoms when
compared with that of vinculin, while the MVt domain (residues
946–1,132) exhibits an r.m.s.d. of 0.8 A ˚ for 163 Ca atoms. The
termini as well as the disordered region are labeled (‘‘N’’ and ‘‘C’’,
and ‘‘855’’ and ‘‘946’’, respectively).
Found at: doi:10.1371/journal.pone.0010679.s004 (6.93 MB TIF)
Figure S4 MVt is more stable than Vt. Normalized thermal
unfolding curves of DN-Vt (residues 891–1066; red) and MVt-
DH1 (residues 959–1130; blue) monitored at 222 nm are shown.
The Tm values indicate that the metavinculin five-helix bundle
(72uC) is significantly more stable compared to the vinculin five-
helix bundle (67uC).
Found at: doi:10.1371/journal.pone.0010679.s005 (1.34 MB TIF)
Figure S5 The extended coil in metavinculin engages in fewer
interactions than that of the extended coil of vinculin. Stereo view
of the Vt (A) and MVt (B) domains of the full-length metavinculin
and vinculin crystal structures reveals that the extended coil in
vinculin engages in more intradomain interactions compared to
metavinculin.
Found at: doi:10.1371/journal.pone.0010679.s006 (6.92 MB TIF)
Figure S6 Fewer intramolcular interactions of the extended coil
of metavinculin compared to the extended coil of vinculin.
Schematic of the intramolecular interactions of the extended coil
of vinculin (A) versus those of metavinculin (B). A: Six extended
coil residues (three of these in only one subunit, indicated by the
red and blue lines) interact with thirteen Vt residues, including five
electrostatic interactions. B: Five metavinculin-specific extended
coil residues engage in eleven hydrophobic/hydrogen bonding
interactions. Indeed, these interactions are only seen in one
subunit (indicated by the blue line), as the metavinculin-specific
extended coil is disordered in the other subunit.
Found at: doi:10.1371/journal.pone.0010679.s007 (2.13 MB TIF)
Figure S7 Intramolecular interactions of the extended coil in
metavinculin and in the Leu954 deletion metavinculin mutant
associated with cardiomyopathies. Residues binding to the wild
type extended coil (A; boxed in light blue) or mutant
metavinculin (B; boxed in peach) are shown on the left (A) or
right (B) of the respective coils. Residues are distinguished
according to the type of their interaction (hydrophobic, white;
hydrogen bonds, gray). The deletion of Leu-954 is indicated by a
dotted line in panel B. Due to the deletion, the numbering for
residues 955–1,134 of wild type metavinculin in the DL954
mutant is 954–1,133.
Found at: doi:10.1371/journal.pone.0010679.s008 (2.17 MB TIF)
Figure S8 Helix replacement does not affect the head:tail
interaction. Reciprocal tail displacement native gel analyses of VH
(residues 1–843) in complex with (A) MVt-Arg975Trp, (B) MVt-
DLeu954, and (C) Vt versus MVt (A and C) or MVt-DH1(B). VH
in complex with MVt or MVt-DLeu954 migrate similarly (ESR
personal communication); thus, MVt-DH1 was used instead of
MVt to be able to distinguish the complexes. Vt and MVt-DH1 do
not migrate into the gel due to their basic pIs of 9.32 and 9.89,
respectively. Competing tail domains were titrated (arrows) into
preformed complexes at 2- and 10-fold molar excess. Notably, the
DCM-associated metavinculin mutant MVt-R975W (A) shows the
weakest head:tail interaction while the tail domains of the two
vinculin isoforms or the DLeu deletion mutant do not affect this
interaction. Representative analyses of native gels are shown. The
less-than sign (,) and asterisk highlight the displaced VH:tail
domain complexes. MVt displaces MVt-Arg975Trp more readily
(A), MVt-DLeu954 and MVt-DH1 displace each other similarly
(B), and MVt and Vt displace each other equally (C).
Found at: doi:10.1371/journal.pone.0010679.s009 (2.17 MB TIF)
Figure S9 a-Helix H19 impairs metavinculin oligomerization. A:
Chromatogram of size exclusion chromatography of full length
metavinculin (red; 123.8 kDa), MV-DH1 (green; 121.3 kDa), and
MV-DH19 (blue; 121 kDa) on a Hiload 26/60 Superdex 200
column calibrated with standard molecular weight markers
(thyroglobulin, 669 kDa; ferritin, 440 kDa; aldolase, 158 kDa;
conalbumin, 75 kDa; and ovalbumin, 43 kDa). The elution
positions of the standard proteins are indicated on the chromato-
gram. The shaded areas for the dimer (‘d’) and monomer (‘m’)
elutants of MV-DH19 indicate the fractions pooled for dynamic
light scattering (panels B and C) and native gel (Figure 4A)
experiments. B: and C: Analysis of the oligomeric state of the two
species, ‘d’ and ‘m’, of MV-DH19 separated by gel filtration (A) by
dynamic light scattering (DLS) at 23uC. DLS measurements were
carried out at a scattering angle of 90u on a Dynapro Titan (Wyatt
technologies) dynamic light scattering apparatus. D: The calcu-
lated molecular weight (MWR) for peak fractions of the two
species of MV-DH1 separated by gel filtration (A) as determined
by dynamic light scattering. Values provided correspond to major
peaks as obtained by DLS experiment. The relative intensity in
this panel represents the relative amount of light scattered by each
population of species in solution while the relative intensities in
panels B and C indicate the relative amount of light scattered by
the bin compared to the other bin and thus differ in values for the
same peak.
Found at: doi:10.1371/journal.pone.0010679.s010 (2.60 MB TIF)
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